دورية أكاديمية
Molecular subtyping improves breast cancer diagnosis in the Copenhagen Breast Cancer Genomics Study.
| العنوان: | Molecular subtyping improves breast cancer diagnosis in the Copenhagen Breast Cancer Genomics Study. |
|---|---|
| المؤلفون: | Berg T; Danish Breast Cancer Group.; Department of Clinical Oncology.; Center for Genomic Medicine, and., Jensen MB; Danish Breast Cancer Group., Celik A; Danish Breast Cancer Group., Talman ML; Department of Pathology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Misiakou MA; Center for Genomic Medicine, and., Knoop AS; Danish Breast Cancer Group.; Department of Clinical Oncology., Nielsen FC; Center for Genomic Medicine, and.; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark., Ejlertsen B; Danish Breast Cancer Group.; Department of Clinical Oncology.; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark., Rossing M; Center for Genomic Medicine, and.; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark. |
| المصدر: | JCI insight [JCI Insight] 2024 Apr 08; Vol. 9 (7). Date of Electronic Publication: 2024 Apr 08. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 101676073 Publication Model: Electronic Cited Medium: Internet ISSN: 2379-3708 (Electronic) Linking ISSN: 23793708 NLM ISO Abbreviation: JCI Insight Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Ann Arbor, Michigan : American Society for Clinical Investigation, [2016]- |
| مواضيع طبية MeSH: | Breast Neoplasms*/diagnosis , Breast Neoplasms*/genetics, Humans ; Female ; Biomarkers, Tumor/genetics ; Prognosis ; Genomics |
| مستخلص: | BACKGROUNDIntrinsic molecular subtypes define distinct biological breast cancers and can be used to further improve diagnosis and risk allocation.METHODSThe Copenhagen Breast Cancer Genomics Study (CBCGS) prospectively included women diagnosed with breast cancer at Rigshospitalet from 2014 to 2021. Eligible patients were females with a primary invasive breast cancer (T1c, if N0M0; otherwise, any T, any N, or any M stage) and no prior malignancy. All patients underwent molecular profiling with the CIT256 and PAM50 molecular profile.RESULTSIn the study period, 2,816 patients were included in the CBCGS. Molecular subtyping showed an increase in nonluminal (molecular-apocrine, luminal C, and Basal-like) as compared with luminal (luminal A, luminal B, and Normal-like) subtypes with increasing stage from I to IV. Across all stages, we found a significant difference in survival among subtypes; 91% of patients with LumA were alive at 5 years compared with 91% for LumB, 84% for LumC, 82% for mApo, and 80% for Basal-like. We identified 442 tumors (16%) that were discordant in subtype between CIT256 and IHC. Discordant subtype proved to be a risk factor of death among patients with IHC luminal breast cancer (hazard ratio [HR], 2.08; 95% CI, 1.51-2.86) in a multivariable Cox regression analysis. Discordance occurred more often among patients with N3, stage IV, or grade III disease.CONCLUSIONOur findings indicate that molecular subtypes are a predominant classification for survival. Assessment is particularly crucial for patients with IHC luminal breast cancer with known high-risk factors, since they are at an increased risk of harboring an aggressive molecular subtype. |
| References: | Acta Oncol. 2018 Jan;57(1):58-66. (PMID: 29164972) J Clin Oncol. 2023 May 10;41(14):2546-2560. (PMID: 36944149) Curr Med Res Opin. 2016 Jul;32(7):1217-24. (PMID: 26971372) Nature. 2002 Jan 31;415(6871):530-6. (PMID: 11823860) Breast Cancer Res. 2023 Feb 8;25(1):17. (PMID: 36755280) Nat Rev Cancer. 2009 Feb;9(2):128-34. (PMID: 19132008) J Clin Oncol. 2009 Mar 10;27(8):1160-7. (PMID: 19204204) Front Public Health. 2014 Jul 29;2:87. (PMID: 25121080) Clin Breast Cancer. 2018 Apr;18(2):e167-e178. (PMID: 28689012) J Clin Oncol. 2013 Aug 1;31(22):2783-90. (PMID: 23816962) Sci Rep. 2021 Jan 26;11(1):2259. (PMID: 33500440) Sci Rep. 2017 Mar 27;7:45411. (PMID: 28345619) N Engl J Med. 2004 Dec 30;351(27):2817-26. (PMID: 15591335) BMC Cancer. 2015 Feb 06;15:35. (PMID: 25655188) Breast Cancer Res Treat. 2021 Oct;189(3):845-852. (PMID: 34331630) Sci Rep. 2019 Aug 21;9(1):12184. (PMID: 31434940) Breast. 2023 Oct;71:42-46. (PMID: 37481795) Breast Cancer Res Treat. 2019 Feb;173(3):533-543. (PMID: 30361874) J Clin Oncol. 2020 Apr 20;38(12):1346-1366. (PMID: 31928404) Control Clin Trials. 1996 Aug;17(4):343-6. (PMID: 8889347) Oncogene. 2012 Mar 1;31(9):1196-206. (PMID: 21785460) Nature. 2000 Aug 17;406(6797):747-52. (PMID: 10963602) Ann Oncol. 2015 Aug;26(8):1685-91. (PMID: 25935792) J Clin Oncol. 2018 Jul 10;36(20):2105-2122. (PMID: 29846122) Mol Oncol. 2018 Dec;12(12):2136-2146. (PMID: 30289602) Breast Cancer Res. 2017 Nov 14;19(1):120. (PMID: 29137653) Acta Oncol. 2018 Jan;57(1):38-43. (PMID: 29172851) N Engl J Med. 2016 Aug 25;375(8):717-29. (PMID: 27557300) JAMA Oncol. 2018 Apr 01;4(4):545-553. (PMID: 29450494) Cancer Epidemiol Biomarkers Prev. 2018 Jun;27(6):619-626. (PMID: 29593010) Breast Cancer Res Treat. 2018 Jan;167(1):123-131. (PMID: 28929359) Eur J Cancer. 2013 Jan;49(2):305-11. (PMID: 22940292) N Engl J Med. 2010 Nov 11;363(20):1938-48. (PMID: 21067385) Cancer Epidemiol Biomarkers Prev. 2012 Oct;21(10):1848-55. (PMID: 22989461) Clin Cancer Res. 2010 Nov 1;16(21):5222-32. (PMID: 20837693) Ann Oncol. 2015 Jan;26(1):81-88. (PMID: 25361981) Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74. (PMID: 11553815) Histopathology. 1991 Nov;19(5):403-10. (PMID: 1757079) Cancer Epidemiol Biomarkers Prev. 2014 May;23(5):725-34. (PMID: 24521998) Cancers (Basel). 2019 Apr 08;11(4):. (PMID: 30965658) Breast Cancer Res Treat. 2020 Jan;179(1):197-206. (PMID: 31542876) CA Cancer J Clin. 2017 Mar;67(2):93-99. (PMID: 28094848) Eur J Cancer. 2020 Apr;129:60-70. (PMID: 32135312) Curr Med Res Opin. 2015 Jun;31(6):1129-37. (PMID: 25851308) J Cancer Res Clin Oncol. 2017 Mar;143(3):509-519. (PMID: 27853869) Cancer Res Treat. 2019 Apr;51(2):737-747. (PMID: 30189722) Breast Cancer Res. 2019 Oct 17;21(1):113. (PMID: 31623649) Exp Mol Pathol. 2020 Jun;114:104404. (PMID: 32067942) Cancer Epidemiol Biomarkers Prev. 2014 May;23(5):714-24. (PMID: 24521995) J Clin Oncol. 2018 Mar 10;36(8):735-740. (PMID: 29369732) Cancer Epidemiol Biomarkers Prev. 2019 Apr;28(4):798-806. (PMID: 30591591) Acta Oncol. 2018 Jan;57(1):51-57. (PMID: 29164968) |
| فهرسة مساهمة: | Keywords: Breast cancer; Clinical practice; Molecular pathology; Oncology |
| المشرفين على المادة: | 0 (Biomarkers, Tumor) |
| تواريخ الأحداث: | Date Created: 20240408 Date Completed: 20240409 Latest Revision: 20240627 |
| رمز التحديث: | 20240627 |
| مُعرف محوري في PubMed: | PMC11128195 |
| DOI: | 10.1172/jci.insight.178114 |
| PMID: | 38587073 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2379-3708 |
|---|---|
| DOI: | 10.1172/jci.insight.178114 |